Abstract |
Matrix metalloproteinase 9 (MMP9) is involved in the proteolysis of extracellular proteins and plays a critical role in pancreatic ductal adenocarcinoma (PDAC) progression, invasion and metastasis. The therapeutic potential of an anti-MMP9 antibody (αMMP9) was evaluated in combination with nab-paclitaxel (NPT)-based standard cytotoxic therapy in pre-clinical models of PDAC. Tumour progression and survival studies were performed in NOD/SCID mice. The mechanistic evaluation involved RNA-Seq, Luminex, IHC and Immunoblot analyses of tumour samples. Median animal survival compared to controls was significantly increased after 2-week therapy with NPT (59%), Gem (29%) and NPT+Gem (76%). Addition of αMMP9 antibody exhibited further extension in survival: NPT+αMMP9 (76%), Gem+αMMP9 (47%) and NPT+Gem+αMMP9 (94%). Six-week maintenance therapy revealed that median animal survival was significantly increased after NPT+Gem (186%) and further improved by the addition of αMMP9 antibody (218%). Qualitative assessment of mice exhibited that αMMP9 therapy led to a reduction in jaundice, bloody ascites and metastatic burden. Anti-MMP9 antibody increased the levels of tumour-associated IL-28 (1.5-fold) and decreased stromal markers ( collagen I, αSMA) and the EMT marker vimentin. Subcutaneous tumours revealed low but detectable levels of MMP9 in all therapy groups but no difference in MMP9 expression. Anti-MMP9 antibody monotherapy resulted in more gene expression changes in the mouse stroma compared to the human tumour compartment. These findings suggest that anti-MMP9 antibody can exert specific stroma-directed effects that could be exploited in combination with currently used cytotoxics to improve clinical PDAC therapy.
|
Authors | Niranjan Awasthi, Amanda J Mikels-Vigdal, Erin Stefanutti, Margaret A Schwarz, Sheena Monahan, Victoria Smith, Roderich E Schwarz |
Journal | Journal of cellular and molecular medicine
(J Cell Mol Med)
Vol. 23
Issue 6
Pg. 3878-3887
(06 2019)
ISSN: 1582-4934 [Electronic] England |
PMID | 30941918
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. |
Chemical References |
- 130-nm albumin-bound paclitaxel
- Acta2 protein, mouse
- Actins
- Albumins
- Antibodies, Monoclonal
- Cytokines
- Vimentin
- interferon-lambda protein, mouse
- Collagen
- MMP9 protein, human
- Matrix Metalloproteinase 9
- Paclitaxel
|
Topics |
- Actins
(metabolism)
- Albumins
(therapeutic use)
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Pancreatic Ductal
(drug therapy, metabolism)
- Cell Line, Tumor
- Collagen
(metabolism)
- Cytokines
(metabolism)
- Female
- Humans
- Matrix Metalloproteinase 9
(genetics, immunology, metabolism)
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Paclitaxel
(therapeutic use)
- Pancreatic Neoplasms
(drug therapy, metabolism)
- RNA-Seq
- Tumor Microenvironment
(drug effects, genetics)
- Vimentin
(metabolism)
- Xenograft Model Antitumor Assays
|